Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
Observing the fourth quarter of 2022 performance, the company's made it had arduous period
company delivered fourth quarter of 2022 operating income of $531.46 million
Published Mar 22 2023
CSIMarket Team / CSIMarket.com
The revenue crumbled by -30.292 % to $2.08 billion from $2.99 billion in the similar quarter a year before and sequentially from $0.00 million.
Net profits of $423.211 million in the fiscal time-frame ending December 31 2022 fell by -17.44 % from $512.599 million in the corresponding period a year before. Qiagen N V also emphasized it's improving profit margins, where net margin rose to 20.34% in fiscal time-frame ending December 31 2022, and operating margin edged up to 25.54%.
Operating earnings, fell -15.65% to $531.46 million, squeezing Qiagen N V 's operating margin to 25.54%, from 21.11% in the fourth quarter of 2021. Looking further into QGENs' reports for the financial 12 Months 2022, company disclosed revenue of $2.08 billion and net income of $423.21 million.
Biotechnology & Pharmaceuticals company mentioned as well, that Profits per share fell by -16.74 % to $1.84 per share from $2.21 in the preceding financial 12 Months , told as well, that Revenue Tumbled by -30.29 % from $2.99 billion a year before.
Qiagen N V is expected to report next financial recent numbers on March 09, 2024.
Other QGEN's news
BioAegis Therapeutics Paves Path to ARDS Paradigm Shift with Revolutionary Gelsolin Study
QIAGEN*s Strong Q4 Performance and Positive Outlook Reflects Growth Potential in Non-COVID Portfolio
Kraken Robotics* AquaPix MINSAS System: A Game-Changer for Mine Countermeasure Operations
Headline: Qiagen N V Sees Significant Decrease in Revenue and Income in Fourth Quarter of 2023
Observing the fourth quarter of 2022 performance, the company*s made it had arduous period
Other QGEN's news
BioAegis Therapeutics Paves Path to ARDS Paradigm Shift with Revolutionary Gelsolin Study
QIAGEN*s Strong Q4 Performance and Positive Outlook Reflects Growth Potential in Non-COVID Portfolio
Kraken Robotics* AquaPix MINSAS System: A Game-Changer for Mine Countermeasure Operations
Headline: Qiagen N V Sees Significant Decrease in Revenue and Income in Fourth Quarter of 2023
Observing the fourth quarter of 2022 performance, the company*s made it had arduous period